Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Longlive Bio-technology is a Chinese industrial biotechnology company that pioneered the biorefinery model using agricultural waste. The company specializes in the production of functional sugars, most notably xylo-oligosaccharides (XOS), which serve as high-purity prebiotics for the food and healthcare industries. Beyond health ingredients, Longlive is a major producer of cellulosic ethanol and lignin, utilizing corn cobs as a primary raw material. The company's integrated technology chain allows for the simultaneous production of value-added chemicals and renewable energy. However, following a series of financial scandals and debt defaults, the company was delisted from the Shenzhen Stock Exchange in 2020.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Longlive Biotechnology.